Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 92 peer-reviewed journal articles Updated
Hematology-Oncology

A Patient's Guide to Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

At a Glance

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare, aggressive blood cancer that typically starts in the skin before spreading to the bone marrow. Treatment requires specialized care and often includes targeted therapies and stem cell transplants.

Receiving a diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) can be incredibly isolating. Because it is so rare, you might find that even medical professionals are unfamiliar with it. This guide is designed to empower you with the knowledge needed to navigate this complex disease, understand your treatment options, and partner effectively with your medical team.

BPDCN is an aggressive blood cancer that most often begins in the skin but can quickly involve the bone marrow and lymph nodes. Fortunately, the landscape of BPDCN treatment has changed dramatically in recent years. With the introduction of targeted therapies and refined transplant protocols, there are now clear, established pathways for care.

This resource guide is broken down into specific topics to help you understand every phase of your journey. Please use the links below to explore the detailed pages:

01

Finding Your Footing After a BPDCN Diagnosis

Just diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)? Learn about targeted therapy like tagraxofusp, stem cell transplants, and next steps.

02

Recognizing the Symptoms and Progression of BPDCN

Learn about the symptoms and progression of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Understand skin lesions, bone marrow impact, and warning signs.

03

Decoding Your Pathology and Flow Cytometry Reports

Learn how to read your BPDCN pathology and flow cytometry reports. Understand key diagnostic markers like CD123, CD4, CD56, and what genetic mutations mean.

04

The Modern Roadmap for BPDCN Treatment

Learn the step-by-step treatment roadmap for BPDCN. Understand induction with tagraxofusp, CNS prophylaxis, and stem cell transplants for long-term remission.

05

Building Your Expert Care Team and Preparing for Your First Visit

Learn how to build an expert care team for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Find out what specialists you need and which records to bring.

06

Understanding Capillary Leak Syndrome and Side Effects

Learn about Capillary Leak Syndrome (CLS), a serious side effect of BPDCN treatment with tagraxofusp (Elzonris). Understand warning signs and monitoring.

07

Life After Transplant and the Path of Survivorship

Learn what to expect during BPDCN survivorship and after an allogeneic stem cell transplant. Understand recovery, GVHD signs, and long-term monitoring.

You are your own best advocate. By understanding the biology of your disease and the standard of care, you can ensure you are receiving the highest quality treatment possible.

Common questions in this guide

What is Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)?
BPDCN is a rare and aggressive blood cancer. It typically begins with a "skin-first" presentation, causing skin lesions, before rapidly spreading to involve the bone marrow and lymph nodes.
What specialists do I need to see for a BPDCN diagnosis?
Because BPDCN is so rare, you need a specialized, multidisciplinary care team. This team should ideally include experts in hematology-oncology, dermatology, and stem cell transplantation at an academic medical center.
What are the standard treatment options for BPDCN?
Modern treatment for BPDCN often involves targeted therapies that focus on specific diagnostic markers like CD123. Depending on your age and health, your plan may also include induction therapy, central nervous system (CNS) prophylaxis, and a stem cell transplant.
What is Capillary Leak Syndrome in BPDCN treatment?
Capillary Leak Syndrome is a critical, potentially severe side effect associated with certain targeted therapies used for BPDCN. It requires close monitoring and often hospital admission to manage safely.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) have you or this cancer center treated in the past five years?
  2. 2.Does your facility have a multidisciplinary team that includes specialists in hematology-oncology, dermatology, and stem cell transplant?
  3. 3.Given my age and overall health, what is the safest and most effective initial treatment plan for my diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

This guide is for informational purposes only and does not replace professional medical advice. Because BPDCN is a rare cancer, always consult with an experienced hematologist-oncologist regarding your specific diagnosis and treatment plan.

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.